View Post

Initial RSV Vaccine Approved in the U.S.

In COVID-19, Latest News by Precision Vaccinations

The U.S. Food and Drug Administration today approved Arexvy™, the first single-dose, respiratory syncytial virus (RSV) vaccine approved for use in the United States.
GSK plc's Arexvy is approved for preventing lower respiratory tract disease (LRTD) caused by RSV in individuals 60 and older.
The U.S. launch is planned before the start of the 2023/24 RSV season.